Study investigator, Dr. Jeffrey Neul, is featured today on NeurologyLive, discussing trofinetide as a potential treatment for Rett syndrome.
NeurologyLive is a media platform for healthcare professionals treating neurological diseases.Dr. Neul points out that, not only is Lavender the first Phase 3 study that has met primary endpoints in Rett syndrome, but it is also one of the first times a successful phase 3 trial has been completed in any neurodevelopmental disorder.
https://www.neurologylive.com/view/trofinetide-as-an-option-rett-syndrome-treatment
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-20
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$20.14 |
Change
0.500(2.55%) |
Mkt cap ! $2.543B | |||
| Open | High | Low | Value | Volume |
| $19.72 | $20.55 | $19.65 | $20.21M | 996.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 400 | $20.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.28 | 1110 | 2 |
View Market Depth
| Last trade - 16.16pm 18/09/2025 (20 minute delay) ? |
| NEU (ASX) Chart |